Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
22,926,692
-
Total 13F shares
-
13,362,268
-
Share change
-
-512,096
-
Total reported value
-
$35,677,274
-
Price per share
-
$2.67
-
Number of holders
-
29
-
Value change
-
-$2,639,076
-
Number of buys
-
11
-
Number of sells
-
12
Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) as of Q2 2025
As of 30 Jun 2025,
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,362,268 shares.
The largest 10 holders included
SAMSARA BIOCAPITAL, LLC, TANG CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, GILEAD SCIENCES, INC., Siren, L.L.C., VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Redmile Group, LLC, Squarepoint Ops LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
29
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.